NASDAQ:MBRX

Moleculin Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy MBRX

*Your capital is at risk

$2.46

+0 (+0%)

At Close: Jun 03, 2026

Moleculin Biotech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.94. In total, the insiders bought 12.36M and sold 21.37K MBRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.94
● Buy	12.36M shares
● Sell	21.37K shares
82% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Jun 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.94. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Cermak Elizabeth Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Yan Joy Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Klemp Walter V CEO And President	CEO / President	830 000 Value: $406.7K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Picker Donald H Cso	Officer	200 000 Value: $98.0K
Nov 12, 2025 Buy	Performance Based Restricted Stock Units A-Award	Picker Donald H Cso	Officer	200 000 Value: $97.5K
Nov 12, 2025 Buy	Performance Based Restricted Stock Units A-Award	Foster Jonathan P. EVP & CFO	C-Suite Officer	400 000 Value: $195.0K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Foster Jonathan P. EVP & CFO	C-Suite Officer	600 000 Value: $294.0K
Nov 12, 2025 Buy	Performance Based Restricted Stock Units A-Award	Klemp Walter V CEO And President	CEO / President	750 000 Value: $365.7K
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Cannon Michael D Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Climaco John M Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	George Robert E. Director	Director	150 000 Value: $73.5K
Nov 04, 2025 Sell	Common Stock F-InKind	Klemp Walter V CEO And President	CEO / President	7 001 Value: $3K
Nov 04, 2025 Buy	Common Stock M-Exempt	Klemp Walter V CEO And President	CEO / President	28 750 Value: $14.3K
Nov 04, 2025 Buy	Restricted Stock Units M-Exempt	Klemp Walter V CEO And President	CEO / President	28 750 Value: $14.3K
Nov 04, 2025 Sell	Common Stock F-InKind	Picker Donald H Chief Science Officer	Officer	2 131 Value: $1K
Nov 04, 2025 Buy	Common Stock M-Exempt	Picker Donald H Chief Science Officer	Officer	8 750 Value: $4K
Nov 04, 2025 Buy	Restricted Stock Units M-Exempt	Picker Donald H Chief Science Officer	Officer	8 750 Value: $4K
Nov 04, 2025 Buy	Restricted Stock Units M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	20 625 Value: $10.2K
Nov 04, 2025 Buy	Common Stock M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	20 625 Value: $10.2K
Nov 04, 2025 Buy	Common Stock M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	5 023 Value: $2K
Jun 23, 2025 Buy	Series E Warrants P-Purchase	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	810 810 Value: $300.0K
Jun 23, 2025 Buy	Common Stock P-Purchase	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	270 270 Value: $100.0K
Jun 23, 2025 Buy	Series E Warrants P-Purchase	Klemp Walter V CEO And President	CEO / President	2 027 025 Value: $750.0K
Jun 23, 2025 Buy	Common Stock P-Purchase	Klemp Walter V CEO And President	CEO / President	675 675 Value: $250.0K
Jun 23, 2025 Buy	Common Stock P-Purchase	Klemp Walter V CEO And President	CEO / President	675 675 Value: $250.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MOLECULIN BIOTECH INC

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...

Read Full Profile Here